Breast Cancer Clinical Trials in Washington D.C., District of Columbia

14 studies are recruiting for breast cancer in Washington D.C., District of Columbia right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Identifying Patterns in the Breath of Individuals With Breast Cancer

   Researchers will compare the breath profiles of women with breast cancer and those without to determine whether there are disease-specific patterns that can be leveraged to facilitate breast cancer detection. Women with mammogram-confirmed breast tissue density undergoing standard-of-care breast ca…

   Stage

   Not phased

   Ages

   40 to 74

   Site

   GW Comprehensive Breast Center, Washington D.C., District of Columbia

   Locations

   5 in total

   Run by

   Breathe BioMedical Inc

   See if you can join NCT06512350 on ClinicalTrials.gov

2. A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

   The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Georgetown University Medical Center, Washington D.C., District of Columbia

   Locations

   567 in total

   Run by

   Stemline Therapeutics, Inc.

   See if you can join NCT06492616 on ClinicalTrials.gov

3. Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

   This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Georgetown University Medical Center, Washington D.C., District of Columbia

   Locations

   231 in total

   Run by

   Relay Therapeutics, Inc.

   See if you can join NCT06982521 on ClinicalTrials.gov

4. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

   This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with es…

   Stage

   Phase 3

   Ages

   18 to 60

   Site

   Kaiser Permanente-Capitol Hill Medical Center, Washington D.C., District of Columbia

   Locations

   1261 in total

   Run by

   NRG Oncology

   See if you can join NCT05879926 on ClinicalTrials.gov

5. TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd

   The purpose of this study is to test the safety and effectiveness of the sequence of two investigational drugs (trastuzumab deruxtecan followed by datopotamab deruxtecan, or datopotamab deruxtecan followed by trastuzumab deruxtecan) to learn whether the treatment works in treating HER2-negative (HE…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Georgetown University Medical Center, Washington D.C., District of Columbia

   Locations

   11 in total

   Run by

   Ana C Garrido-Castro, MD

   See if you can join NCT06533826 on ClinicalTrials.gov

6. Gut Microbiome, Adverse Effects, and Markers Through MEtabolic Reprogramming

   This research is being done to test the feasibility of 24-48 hours of water-only fasting to improve delivery of 4 cycles of chemotherapy in those receiving breast cancer treatment either before or after surgery.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Sibley Memorial Hospital, Washington D.C., District of Columbia

   Run by

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

   See if you can join NCT06536881 on ClinicalTrials.gov

7. Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

   This is a prospective, randomized, double-blinded, placebo-controlled, multi-center, Phase 3 study of GLSI-100 immunotherapy in HLA-A*02 positive and HER2/neu positive subjects who are at high risk for disease recurrence and have completed both neoadjuvant and postoperative adjuvant standard of car…

   Stage

   Phase 3

   Ages

   18 to 100

   Site

   Johns Hopkins Medicine - Kimmel Cancer Center-Sibley Memorial Hospital, Washington D.C., District of Columbia

   Locations

   179 in total

   Run by

   Greenwich LifeSciences, Inc.

   See if you can join NCT05232916 on ClinicalTrials.gov

8. E-Mindfulness Approaches for Living After Breast Cancer

   NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and an app-based, self-paced version (MAPs App). Participants wi…

   Stage

   Phase 3

   Ages

   18 to 50

   Site

   Kaiser Permanente-Capitol Hill Medical Center, Washington D.C., District of Columbia

   Locations

   383 in total

   Run by

   NRG Oncology

   See if you can join NCT06748222 on ClinicalTrials.gov

9. I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

   The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic res…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Georgetown University Medical Center, Washington D.C., District of Columbia

   Locations

   42 in total

   Run by

   QuantumLeap Healthcare Collaborative

   See if you can join NCT01042379 on ClinicalTrials.gov

10. A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

    The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positive breast cancer cells have proteins on their surface called…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    MedStar Washington Hospital Center, Washington D.C., District of Columbia

    Locations

    202 in total

    Run by

    Pfizer

    See if you can join NCT07062965 on ClinicalTrials.gov

11. Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer

    This clinical trial will assess the safety and early efficacy of Hydroxychloroquine or Avelumab, with or without Palbociclib, in early-stage ER+ breast cancer patients who are found to harbor disseminated tumor cells (DTCs) in the bone marrow after definitive surgery and standard adjuvant therapy.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Georgetown University, Washington D.C., District of Columbia

    Locations

    7 in total

    Run by

    Abramson Cancer Center at Penn Medicine

    See if you can join NCT04841148 on ClinicalTrials.gov

12. The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer

    The investigators propose a randomized controlled clinical trial in 250 women with a history of early stage breast cancer who are overweight or obese with insomnia to test whether a brief, cognitive-behavioral intervention for insomnia (CBT-I) prior to behavioral weight loss (CBT-I+BWL) is superior…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Sibley Memorial Hospital, Washington D.C., District of Columbia

    Locations

    4 in total

    Run by

    Johns Hopkins University

    See if you can join NCT05780814 on ClinicalTrials.gov

13. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Georgetown University Medical Center, Washington D.C., District of Columbia

    Locations

    39 in total

    Run by

    SystImmune Inc.

    See if you can join NCT05983432 on ClinicalTrials.gov

14. Improving Genetic Counseling for BRCA+ Mothers

    Genetic counseling and testing for hereditary breast cancer may reveal that you, and possibly your blood relatives, are at increased risk for the disease across the lifespan. This includes biological children, both male and female. We do not yet know the best ways to educate mothers who have a risk…

    Stage

    Not phased

    Ages

    18 and older

    Site

    MedStar Georgetown University Hospital, Washington D.C., District of Columbia

    Run by

    Georgetown University

    See if you can join NCT04258280 on ClinicalTrials.gov